Sign In
Buy INSM
$103.86
+0.130 (+0.125%)
At Close: Jun 03, 2026
Keybank National Association OH Has $2.41 Million Stock Holdings in Insmed, Inc. $INSM
04:40am, Tuesday, 03'rd Feb 2026
Keybank National Association OH grew its stake in shares of Insmed, Inc. (NASDAQ: INSM) by 76.7% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange
Insmed: A Brensocatib Pipeline Setback Is Masking A Dupixent-Like Launch
08:15am, Monday, 02'nd Feb 2026
Insmed remains a compelling buy after an ~30% pullback, as Brinsupri's blockbuster launch trajectory outpaces initial expectations. Brinsupri delivered $144.6M in Q4 sales and 11,550 patient starts in
Artisan Global Opportunities Fund Q4 2025 Portfolio Update
09:39am, Thursday, 29'th Jan 2026
Among our top contributors in Q4 were Argenx, Lam Research and Insmed. Among our biggest detractors in Q4 were Oracle, Netflix and BAE Systems. During the quarter, we initiated new positions in RTX (R
—Abstracts Include the Phase 3 PALM-PAH Study Design, a Presentation of the Previously Disclosed Topline Phase 2b PAH Data, a Functional Respiratory Imaging Analysis from the Phase 2b Study in Pulmo
Universal Beteiligungs und Servicegesellschaft mbH Trims Stake in Insmed, Inc. $INSM
05:48am, Monday, 26'th Jan 2026
Universal Beteiligungs und Servicegesellschaft mbH cut its stake in shares of Insmed, Inc. (NASDAQ: INSM) by 36.9% during the undefined quarter, according to its most recent Form 13F filing with the S
William Lewis Sells 10,699 Shares of Insmed (NASDAQ:INSM) Stock
04:51am, Saturday, 24'th Jan 2026
Insmed, Inc. (NASDAQ: INSM - Get Free Report) CEO William Lewis sold 10,699 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $158.93, for a tota
Artisan Small Cap Fund Q4 2025 Portfolio Activity
09:08am, Friday, 23'rd Jan 2026
During the quarter, we initiated new positions in nLIGHT, Guardant Health and Cellebrite. We also added to Bruker, Hexcel and Penumbra during the quarter. Along with Insmed, we also ended our investme
Pre-Market Stock Futures: Futures are trading lower as we prepare to wrap up a rollercoaster week marked by huge market swings. Still, ultimately, President Trump's TACO (Trump Always Chickens Out) mo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
10:00am, Thursday, 22'nd Jan 2026
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated ("Insmed" or the "Company") (NASDAQ: INSM). Such investors are advised to c
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
10:00am, Thursday, 15'th Jan 2026
NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated ("Insmed" or the "Company") (NASDAQ: INSM). Such investors are advised to c
Insmed (NASDAQ:INSM) CEO William Lewis Sells 19,215 Shares
04:48am, Wednesday, 14'th Jan 2026
Insmed, Inc. (NASDAQ: INSM - Get Free Report) CEO William Lewis sold 19,215 shares of the firm's stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $169.00,
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
04:27pm, Tuesday, 13'th Jan 2026
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated (“Insmed” or the “Company”) (NASDAQ: INSM). Such investors ar
Insmed Incorporated (INSM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
08:16pm, Monday, 12'th Jan 2026
Insmed Incorporated (INSM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Insmed CEO Will Lewis talks its rare disease drug pipeline
06:14pm, Monday, 12'th Jan 2026
Will Lewis, Insmed CEO, joins 'Fast Money' to talk the rare disease pipeline, acquisitions in the pharma space, and more.
INSM Stock Jumps on 2025 Preliminary Sales, 2026 Goals Announced
10:36am, Monday, 12'th Jan 2026
Shares of Insmed rise after it tops FY25 sales forecasts, led by strong Brinsupri uptake, and outlines 2026 guidance and pipeline milestones.
